Key facts
- This page summarizes ARDSLEY ADVISORY PARTNERS LP's Form 4 filing for MARRONE BIO INNOVATIONS INC.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Nov 2021, 15:28.
ARDSLEY ADVISORY PARTNERS LP - 11 Nov 2021 Form 4 Insider Report for MARRONE BIO INNOVATIONS INC
- Reporting relationship
- Other*, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 11 Nov 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Nov 2021, 15:28:52 UTC
- Prior SEC filing
- 05 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steve Napoli, Partner
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
ARDSLEY ADVISORY PARTNERS LP filed Form 4 for MARRONE BIO INNOVATIONS INC on 15 Nov 2021.
Change
- Previous filing in this sequence was filed on 05 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MBII
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $463,510
- Shares
- +618,014
- Change %
- +3.5%
- Price
- $0.7500
- Shares after
- 18,335,767
- Date
- 11 Nov 2021
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MBII
transaction
Derivative
Warrant
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $463,510
- Shares
- -618,014
- Change %
- -100%
- Price
- $0.7500
- Shares after
- 0
- Date
- 11 Nov 2021
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 618,014
- Exercise price
- $0.7500
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This Form 4 is being filed by Ardsley Advisory Partners LP (the "Advisor") on behalf of itself and Ardsley Advisory Partners GP LLC (the "Advisor General Partner"), Ardsley Partners I GP LLC (the "General Partner"), Ardsley Partners Renewable Energy Fund, L.P. (the "Renewable Energy Fund"), Ardsley Partners Advanced Healthcare Fund, L.P. (the "Advanced Healthcare Fund"), Ardsley Partners Fund II, L.P. (the "Fund II"), and Philip J. Hempleman ("Hempleman" and, together with the Advisor, the Advisor General Partner, the General Partner, the Renewable Energy Fund, the Advanced Healthcare Fund, and the Fund II, the "Reporting Persons"). The Advisor General Partner serves as general partner to the Advisor. The General Partner serves as general partner to the Renewable Energy Fund, the Advanced Healthcare Fund, and the Fund II. Hempleman services as managing member to the Advisor, the Advisor General Partner, and the General Partner.
Footnote F2
The amounts set forth in Table I reflect the shares of Common Stock acquired by the Renewable Energy Fund upon exercise of the Warrants requiring the filing of this statement. In accordance with Instruction 4(b)(iv) of Form 4, the entire amount of the Issuer's securities held by the Reporting Persons is reported herein. Each of the Reporting Persons disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the Advisor, the Advisor General Partner, the General Partner, or Hempleman are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Footnote F3
In accordance with Instruction 4(b)(iv) of Form 4, the entire amount of the Issuer's securities held by the Reporting Persons is reported herein. Each of the Reporting Persons disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the Advisor, the Advisor General Partner, the General Partner, or Hempleman are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.